No Data
No Data
Top Gap Ups and Downs on Thursday: NVS, PGR, INFY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Swiss pharma giant Novartis AG (NYSE:NVS) reported a second-quarter adjusted EPS of $1.97, up 21% year over year (+17% on constant currency), beating the consensus of $1.89.The company's sales
Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk
0748 GMT - Novartis's prostate-cancer drug Pluvicto missed sales expectations in 2Q, whcih might raise questions regarding the company's growth drivers, Bryan Garnier Research analysts say in a note.
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
All growth rates mentioned below are on a year-over-year basis and at constant exchange rates.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Tech Stocks Recover
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Thursday's premarket activity, as tech stocks
Novartis Shares Are Trading Lower. The Company Reported Q2 Financial Results.
Novartis Shares Are Trading Lower. The Company Reported Q2 Financial Results.
No Data